# US 2021/0341468 A1 · Fluorescence counting system for quantifying viruses or antibodies on an immobilized metal substrate by using an antigen-antibody reaction

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0341468 A1
- Document ID: US20210341468A1
- Status: Published application
- Kind: A1
- Application number: 17/096,678
- Filed: 2020-11-12
- Published: 2021-11-04
- Earliest claimed: 2020-04-30
- Assignees: Mytech Corporation
- Applicants: Mytech Co. Ltd.
- Inventors: Yuki Hasegawa; Katsuyuki Hasegawa
- Web page: https://patentgrep.com/patent/US20210341468A1

## CPC

- G01N 33/54306: {Solid-phase reaction mechanisms}
- G01N 33/588: {with semiconductor nanocrystal label, e.g. quantum dots}
- G01N 33/553: Metal or metal coated
- G01N 33/56983: {Viruses}
- G01N 33/6854: {Immunoglobulins}
- G01N 2333/165: Coronaviridae, e.g. avian infectious bronchitis virus
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to a system capable of performing simple and rapid inspection of an antigen equivalent to the immune chromatographic method with accuracy good as a PCR method. An embodiment relates to a novel fluorescence counting system for quantifying viruses or antibodies in an analyte which comprises an unit of providing an antigen or antibody phase solidified substrate by an aggregation method with quantum crystals, an unit for making a labeling liquor and labeling a virus or an antibody to be measured in the analyte by an antigen-antibody method, an unit of exciting the fluorescently labeled virus or antibody by a surface plasmon excitation method, and an unit of counting fluorescent points in an excited fluorescent screen to quantify the virus or antibody in the analyte.

## Claims

### Claim at position 1

1-17. (canceled)

### Claim 18

A method comprising:
adding a plasmon metal complex solution comprising a plasmonic metal complex and a buffer solution of a first antibody onto a metal substrate;
forming a phase solidified substrate comprising the metal substrate and a coagulated plasmon metal complex comprising quantum crystals of the plasmonic metal complex with a size in a range of about 50 nm to about 150 nm, wherein the first antibody is immobilized on the coagulated plasmon metal complex on the phase solidified metal substrate to form an immobilized first antibody;
labeling a target with a fluorescent material;
capturing the target to the immobilized first antibody using an antigen-antibody reaction on the coagulated plasmon metal complex;
making a fluorescence image of the target captured to the immobilized first antibody by irradiating an exciting light;
observing the fluorescence image by a microscope;
counting fluorescence points; and
quantifying the target.

### Claim at position 3

19-27. (canceled)

### Claim 28 (depends on 18)

The method of claim 18, wherein the fluorescence image is binarized with an analysis condition comprising one or more of a brightness, an area, and a circularity of the fluorescence points in the fluorescence image.

### Claim 29 (depends on 28)

The method of claim 28, wherein the analysis condition comprises the brightness and the area in the fluorescence image.

### Claim 30 (depends on 18)

The method of claim 18, wherein the target comprises an antigen or an antibody to be measured in an analyte.

### Claim 31 (depends on 18)

The method of claim 18, wherein the method is compatible to detect more than one of type of the target simultaneously.

### Claim 32 (depends on 31)

The method of claim 31, wherein the target comprises a virus comprising COVID-19 virus comprising SARS-CoV-2.

### Claim 33 (depends on 18)

The method of claim 18, wherein the target is labelled by a sandwich method or a direct method or an indirect method.

### Claim 34

(canceled)

### Claim 35

A method for detecting a virus that causes COVID-19 by detecting a SARS-CoV-2 virus or a SARS-CoV-2 virus-specific antibody comprising:
adding a plasmon metal complex solution comprising a plasmonic metal complex with a buffer solution of a first antibody onto a metal substrate;
forming a phase solidified substrate comprising the metal substrate and a coagulated plasmon metal complex comprising quantum crystals of the plasmonic metal complex with a size in a rang of about 50 nm to about 150 nm, wherein the first antibody is immobilized on the coagulated plasmon metal complex on the phase solidified substrate to form an immobilized first antibody;
labeling a target comprising the SARS-CoV-2 virus or the SARS-CoV-2 virus-specific antibody with a fluorescent material;
capturing the target comprising the SARS CoV-2 virus or the SARS-CoV-2 virus-specific antibody with the immobilized first antibody on the coagulated plasmon metal complex using an antigen-antibody reaction;
making a fluorescence image of the target captured on the immobilized first antibody on the coagulated plasmon metal complex by irradiating an exciting light;
observing the fluorescence image by a microscope;
counting fluorescence points; and
quantifying the target.

### Claim at position 12

36-51. (canceled)

### Claim 52 (depends on 18)

The method of claim 18, wherein the phase solidified substrate is configured to be formed by a phase solidifying unit, wherein the phase solidifying unit comprises the buffer solution of the first antibody and the plasmonic metal complex solution, wherein the buffer solution has a pH of about 7 or more, wherein the metal substrate has an electrode potential more than that of the plasmonic metal complex solution.

### Claim 53 (depends on 18)

The method of claim 18, wherein the plasmonic metal complex solution comprising a density of the plasmonic metal complex in a range of 1000 to 5000 ppm.

### Claim 54 (depends on 52)

The method of claim 52, wherein the phase solidifying unit is dropped onto the metal substrate and coagulating to form a coagulated plasmon metal complex with an immobilized first antigen or an immobilized first antibody, and blowing an air using a device to stop agglomeration of coagulated plasmon metal complex on the metal substrate.

### Claim 55 (depends on 54)

The method of claim 54, wherein the coagulated plasmon metal complex is substantially free of agglomeration of the quantum crystals of the plasmonic metal complex with each other.

### Claim 56 (depends on 18)

The method of claim 18, wherein a fluorescence labeling unit comprised of labeling fluorescence material is configured to label the target to form the labeled target, wherein the fluorescence labeling unit is dropped on the metal substrate to form the labeled target attached to the coagulated plasmon metal complex.

### Claim 57

(canceled)

### Claim 58 (depends on 18)

The method of claim 18, wherein a fluorescence counting unit is configured to count the fluorescence points.

### Claim 59 (depends on 58)

The method of claim 58, wherein the fluorescence counting unit is configured to binarize the fluorescence image into the fluorescence points and quantitively count the fluorescence points.

### Claim 60 (depends on 35)

The method of claim 35, wherein the phase solidified substrate is configured to be formed by a phase solidifying unit, wherein the phase solidifying unit comprises the buffer solution of the first antibody and the plasmonic metal complex solution, wherein the buffer solution has a pH of about 7 or more, wherein the metal substrate has an electrode potential more than that of the plasmonic metal complex solution.

### Claim 61 (depends on 60)

The method of claim 60, wherein the plasmonic metal complex solution comprising a density of the plasmonic metal complex in a range of 1000 to 5000 ppm.

### Claim 62

A method comprising:
adding a plasmon metal complex solution comprising a plasmonic metal complex and a buffer solution of a first antigen onto a metal substrate;
forming a phase solidified substrate comprising the metal substrate and a coagulated plasmon metal complex comprising quantum crystals of the plasmonic metal complex with a size in a range of about 50 nm to about 150 nm, wherein the first antigen is immobilized on the coagulated plasmon metal complex on the phase solidified metal substrate to form an immobilized first antigen;
labeling a target with a fluorescent material;
capturing the target to the immobilized first antigen using an antigen-antibody reaction on the coagulated plasmon metal complex;
making a fluorescence image of the target captured to the immobilized first antigen by irradiating an exciting light;
observing the fluorescence image by a microscope;
counting fluorescence points; and
quantifying the target.

### Claim 63 (depends on 62)

The method of claim 62, wherein the phase solidified substrate is configured to be formed by a phase solidifying unit, wherein the phase solidifying unit comprises the buffer solution of the first antigen and the plasmonic metal complex solution, wherein the buffer solution has a pH of about 7 or more, wherein the metal substrate has an electrode potential more than that of the plasmonic metal complex solution.

### Claim 64 (depends on 62)

The method of claim 62, wherein the plasmonic metal complex solution comprising a density of the plasmonic metal complex in a range of 1000 to 5000 ppm.
